Technology Description

University researchers have invented an approach to develop compounds the use of which would lessen the need for surgical placement and replacement of intravitreal implants for treating chronic vitreoretinal diseases. Frequent injections of therapies can lead to retinal detachment and endophthalmitis, and are extremely inconvenient to the patient. By developing a compound that has the property of being intravitreally injectable and long-acting, University researchers have come up with a way to administer therapy to the eye that does not require surgery or frequent injections. Animal studies have confirmed that the half-life of a therapeutic may be extended to between 8 to 20 weeks, or more.

Patent Status

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	8,017,135	09/13/2011	2003-113

Inventors

• Freeman, William R.

Other Information

Contact

University of California, San Diego Technology Transfer Office / invent@ucsd.edu / tel: View Phone Number. Please reference Tech ID #19662.

Request Additional Information

PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS

• Marine Organism Yields a Patented Family of Antitumor/Antibiotic Compounds
• New Drug Derivatives for Promoting Oral Delivery to the Lung
• Transcription Factor For The Regulation Of The Development Of Skin And Hair
• Treatment for Type II Diabetes and Cancer by Regulating Glucose Transporter Levels
• Novel, Validated Target for Type II Diabetes Drug Inhibitors